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SUMMARY
The discovery that miRNAs are frequently deregulated in tumours offers the opportunity to identify them as prognostic and diagnostic 
markers. The aim of this multicentric study is to identify a miRNA expression profile specific for laryngeal cancer. The secondary endpoint 
was to identify specific deregulated miRNAs with potential as prognostic biomarkers for tumour spread and nodal involvement, and spe-
cifically to search for a miRNA pattern pathognomonic for N+ laryngeal cancer and for N- tissues. We identified 20 miRNAs specific for 
laryngeal cancer and a tissue-specific miRNA signature that is predictive of lymph node metastases in laryngeal carcinoma characterised 
by 11 miRNAs, seven of which are overexpressed (upregulated) and four downregulated. These results allow the identification of a group 
of potential specific tumour biomarkers for laryngeal carcinoma that can be used to improve its diagnosis, particularly in early stages, as 
well as its prognosis.
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RIASSUNTO 
La scoperta che i microRNA sono frequentemente deregolati nei tumori consente di utilizzarli come marker prognostici e diagnostici. Lo 
scopo di questo studio multicentrico è stato stilare un profilo di espressione di miRNA specifico per il  carcinoma della laringe. L’obiettivo 
secondario è stato identificare particolari miRNA deregolati da usare come potenziali biomarker predittivi di diffusione tumorale e di coin-
volgimento linfonodale, nello specifico è stato ricercare un pattern di miRNA patognomonico per tessuto di carcinoma della laringe N+ 
e per N- rispettivamente. Gli Autori hanno identificato venti miRNA specifici per carcinoma della laringe ed inoltre una miRNA signature 
tessuto-specifica predittiva di metastasi linfonodali da carcinoma della laringe caratterizzata da 11 miRNA, sette dei quali over-espressi 
(up-regolati) e quattro  down-regolati. Questi risultati permettono l’identificazione di un gruppo di potenziali biomarker tumore-specifici 
per il carcinoma della laringe che potrebbe essere usata per migliorare la sua diagnosi, in particolare negli stadi iniziali, e soprattutto per 
la sua prognosi.
PAROLE CHIAVE: Carcinoma della laringe • miRNA • Metastasi linfonodali • Profilo di espressione dei miRNA • Fattori prognostici
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Introduction
Laryngeal squamocellular carcinoma (LSCC) accounts 
for approximately 2% of all tumours 1, with an incidence 
of 39,900 new cases per 100,000 people in 2012 and a 
male-female ratio of 8.8:0.8 (9:0.7 in Italy)  2. It is consid-
ered the second most frequent neoplasia of the respiratory 
system after lung cancer. 
Mortality estimated for LSCC was 19,800 cases per 
100,000 in 2012 in Europe, with a male-female ratio of 
4.3:0.3 (3.3:0.3 in Italy) 2.
Specific survival for larynx tumour is conditioned by 
many prognostic factors; the presence of cervical nodal 
metastasis represents the single most important prognos-
tic factor 3 4. The 2-year overall survival of pN+s patients 
is reduced by 40-50% (88.01% in the pN0 vs. 41.54% in 
pN+) 4.
At present, there are no valid prognostic factors that can 
systematically drive the choice of nodal treatment in la-
ryngeal carcinoma 5.
It is a consensus opinion in the literature that biomolecu-
lar markers can fill this deficiency 6 9, especially consider-
ing the high potential of the studies on miRNAs.
miRNAs are small non-coding RNAs that regulate post-
transcriptional gene expression through mechanisms of 
degradation of the messenger (only in vegetables and 
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bugs) or simple sequestration with inhibition of transla-
tion (the mechanism present in humans) 10 11. 
An important feature of miRNAs is their ability to take 
part simultaneously in different pathways through the 
contemporary interaction with multiple messenger tar-
gets. Currently there are many studies that show the key 
role of miRNAs in the genesis, progression and metastatic 
ability of tumours 12 14. 
Different miRNAs are implicated in tumorigenesis by 
acting through oncogenes or through tumor-suppressor 
genes, therefore their expression in tumoural tissues, in 
comparison to healthy tissue, can reveal under- or over-
expression 15.
The discovery that miRNAs are frequently deregulated in 
tumours offers the opportunity to identify them as prog-
nostic and diagnostic markers.
The aim of this multicentric study wasn to identify a 
miRNA expression profile specific for laryngeal cancer. 
The secondary endpoint was to identify specific deregu-
lated miRNAs with potential as prognostic biomarkers of 
tumour spread and nodal involvement, and specifically a 
miRNA pattern pathognomonic for N+ laryngeal cancer 
and for N- tissues.
Materials and methods
Patient enrollment
This study included 24 patients suffering from laryngeal 
carcinoma, 22 males and 2 females, with an average age 
of 60 years (39-77). All the patients came from Campania 
and were treated for a laryngeal tumour at the Complex 
Operative Unit (COU) of Otorhinolaryngology of the 
University Hospital Policlinico “Federico II”, at the COU 
of Otorhinolaryngology and Cervico-facial Surgery of 
the Hills Specialist Hospital Monaldi-Cotugno-CTO and 
at the COU of Otorhinolaryngology of the “A. Cardarel-
li” National Relief Hospital from January to June 2014. 
All patients underwent the following diagnostic proce-
dures:
1. Laryngeal endoscopy.
2. Computerised tomography (CT) of the neck and chest 
with and without contrast. 
3. Multiple laryngeal biopsies with histological examina-
tion.
The TNM classification was applied in all cases accord-
ing to the 2010 AJCC criteria.All patients were submit-
ted to “open” laryngeal surgery and bilateral nodal cer-
vical emptying. In all cases a sample of approximately 
1 cm x 0.5 cm was withdrawn both from healthy tissue 
and macroscopically tumoral tissue from the removed 
larynx, which was immediately introduced into RNA 
later® tubes. The same patients were submitted to blood 
draw, and serum was subsequently cryopreserved at 
-80°C.
The study was approved by the respective Ethics Com-
mittees.
Extraction of miRNAs
The RNA was drawn out using the mirVana PARIS kit 
(Ambion) according to the protocol described by the sup-
plier. A 0.5 mg sample of tumour tissue and the same 
quantity of healthy tissue were used. The concentration of 
the RNA was determined using a Nano Drop spectropho-
tometer by nanodrop reading.
Expression profile of miRNAs 
The miRNA expression profile was determined using the 
TaqMan Array Card Type A (Life Technologies) accord-
ing to the protocol Megaplex pool A. Experiments were 
performed on a thermocycler Viia7 (Life Technologies, 
Inc.), and the relative expression was computed by using 
the 2−ΔΔCT formula and normalised using the endogenous 
U6. For the determination of miRNAs, we used standard 
cards that allow assessment of 382 different miRNAs of 
known function. The cards were provided by the manu-
facturer and used following the manufacturer’s instruc-
tions (Life Technologies, Inc.).
Analysis of miRNA expression profile in laryngeal 
tumoural tissues
The RNA extracted from patients’ samples was assem-
bled into two pools, the first including patients with 
stage T3 and T4 tumours and nodal involvement (N+) 
and the second comprising patients with stage T3 and 
T4 tumours without nodal involvement (N-). The con-
trol pool consisted of RNA extracted from healthy bi-
opsy tissue taken from the same patients enrolled for 
pools N+ and N-.
Results
All patients were submitted to “open” surgery of the lar-
ynx (2 OSL, 3 CHEPs, 19 total laryngectomies). 
In all patients, histological examination led to a di-
agnosis of squamous cell carcinoma. After histologi-
cal examination, patients were classified according to 
both the TNM and histological grading as detailed in 
Table I.
The pTNM scores of the 24 treated patients and grading 
were as follow:
• 17 pT3, 7 pT4;
• 12 pN0, 3 pN1, 7 pN2, 2 pN3;
• 11 G2, 12 G3, 1 G4.
All patients included in the study of miRNA expression 
were selected with homogeneous characteristics regard-
ing both T (pT3 and pT4) and grading. These 24 pa-
tients were then divided into two homogenous groups 
with respect to age, T stage and histological grade on 
the basis of lymph node involvement found in histologi-
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cal examination: 12 patients were pN+ and 12 patients 
pN-, respectively.
The characteristics of patients based upon the degree of 
T and presence of lymph node involvement in selected 
patients were:
• 9 patients pT3N0;
• 8 patients pT3N+; 
• 3 patients pT4N0;
• 4 patients pT4N+.
The miRNAs extracted from the 24 selected patients were 
analysed, and the results of differential expression of miR-
NAs are described below and shown in Tables II to VI.
Expression analysis showed that normal tissues expressed 
180/382 miRNAs, the N- pool expressed 207/382 miR-
NAs and the N+ pool expressed 200/382 miRNAs.
Comparative analysis between the N+ and N- pools and 
the control pool showed that in both groups of patients, 89 
miRNAs were overexpressed compared to normal tissue 
counterparts, and are collected in three groups in Table II 
on the basis of their relative expression; 17 miRNA were 
downregulated, and are shown in Table III. 
Analyzing the N+ and N- pools separately and comparing 
them to healthy control tissues from the same patient, it is 
Table I. p TNM, Grading and laryngectomy type of the 24 patients enrolled 
in the study. 
Number pTNM Grading Laryngectomy 
type
1 T3N2 G3 Total
2 T4N2 G2 Total
3 T3N3 G2 Total
4 T4N2 G3 Total
5 T3N0 G2 Total
6 T4N0 G2 Total
7 T3N0 G2 Total
8 T3N2 G3 Osl
9 T3N0 G3 Chep
10 T3N1 G3 Total
11 T4N0 G3 Total
12 T4N1 G2 Total
13 T3N0 G3 Total
14 T4N3 G3 Total
15 T3N1 G4 Total
16 T3N0 G3 Total
17 T3N2 G2 Chep
18 T3N2 G3 Osl
19 T3N0 G2 Total
20 T3N2 G2 Total
21 T3N0 G3 Total
22 T4N0 G3 Total
23 T3N0 G2 Total
24 T3N0 G2 Chep
Table II. miRNAs overexpressed in tumour tissues in comparison with 
healthy tissues in patients with LSCC.
miRNAs with
fold change >10
miRNAs with
5 < fold change < 10
miRNAs with
2 < fold change < 5
hsa-miR-106b hsa-let-7d hsa-let-7a-
hsa-miR-10b hsa-miR-101 hsa-let-7e-
hsa-miR-130b hsa-miR-103 hsa-let-7 g-
hsa-miR-15b hsa-miR-106a hsa-miR-10a-
hsa-miR-185 hsa-miR-135b hsa-miR-125b-
hsa-miR-19a hsa-miR-141 hsa-miR-127-
hsa-miR-205 hsa-miR-142-5p hsa-miR-130a-
hsa-miR-20a hsa-miR-15a hsa-miR-132-
hsa-miR-21 hsa-miR-17 hsa-miR-138
hsa-miR-221 hsa-miR-181a hsa-miR-148a
hsa-miR-25 hsa-miR-182 hsa-miR-149
hsa-miR-299-5p hsa-miR-193a-5p hsa-miR-152
hsa-miR-455 hsa-miR-19b hsa-miR-155
hsa-miR-494 hsa-miR-210 hsa-miR-192
hsa-miR-511 hsa-miR-223 hsa-miR-194
hsa-miR-598 hsa-miR-23b hsa-miR-199a-3p
hsa-miR-708 hsa-miR-27a hsa-miR-200a
hsa-miR-9 hsa-miR-27b hsa-miR-200b
hsa-miR-340 hsa-miR-203
hsa-miR-34a hsa-miR-24
hsa-miR-429 hsa-miR-26b
hsa-miR-532 hsa-miR-28-3p
hsa-miR-655 hsa-miR-29a
hsa-miR-660 hsa-miR-29b
hsa-miR-886-3p hsa-miR-29c
hsa-miR-92a hsa-miR-301b
hsa-miR-99b hsa-miR-30b
hsa-miR-30c
hsa-miR-32
hsa-miR-324-5p
hsa-miR-331
hsa-miR-335
hsa-miR-337-5p
hsa-miR-374
hsa-miR-422a
hsa-miR-425-5p
hsa-miR-454
hsa-miR-483-5p
hsa-miR-508
hsa-miR-532-3p
hsa-miR-590-5p
hsa-miR-744
hsa-miR-758
hsa-miR-99a
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evident that 12 miRNAs were differentially expressed 
in the two groups of patients and compared to healthy 
control tissue (Table IV). In particular, 4 miRNAs were 
overexpressed in N+ patients with respect to both the 
N- and healthy tissues, 3 miRNAs were downregulated 
in N+ patients compared to both the N- and healthy tis-
sues, 2 were overexpressed in N- patients with respect 
to both the N+ and healthy tissues, 2 miRNAs were 
downregulated in N- patients compared to both N+ and 
healthy tissues, 1 was overexpressed in N+ patients 
compared to healthy tissues and downregulated in N- 
patients compared to the healthy tissue of 24 selected 
patients with LSCC.
Twenty miRNAs were expressed only in the two groups 
of patients (N+ and N-) and not in healthy control tissues 
from the same patients (Table V). Therefore, these miR-
NAs are expressed only in tumour tissues.
Fifteen miRNAs were expressed only in the N+ group, 
and 23 miRNAs were expressed only in the N- group (Ta-
ble VI).
Table III. miRNAs downregulated in tumor tissues in comparison with 
healthy tissues of patients with LSCC.
miRNA N- fold change N+ fold change
hsa-miR-1 0.072 0.040
hsa-miR-126 0.528 0.592
hsa-miR-133a 0.016 0.009
hsa-miR-133b 0.118 0.046
hsa-miR-139-5p 0.210 0.354
hsa-miR-140-3p 0.378 0.333
hsa-miR-186 0.857 0.497
hsa-miR-204 0.514 0.507
hsa-miR-375 0.175 0.742
hsa-miR-449 0.125 0.013
hsa-miR-449b 0.445 0.139
hsa-miR-486 0.403 0.450
hsa-miR-489 0.588 0.605
hsa-miR-539 0.195 0.154
hsa-miR-574-3p 0.705 0.385
hsa-miR-628-5p 0.549 0.440
hsa-miR-885-5p 0.222 0.130
Table IV. Twelve miRNAs with different expression between the two groups 
of patients (N-, N+). miRNAs overexpressed are in red, miRNAs downregu-
lated compared to healthy control tissue of patients with LSCC are in blue.
miRNA N- fold change N+ fold change
hsa-let-7b 1.391 2.437
hsa-miR-135a 0.631 3.538
hsa-miR-20b 1.467 3.981
hsa-miR-212 0.147 0.756
hsa-miR-324-3p 1.375 2.476
hsa-miR-328 1.482 0.519
hsa-miR-365 3.353 1.352
hsa-miR-376a 1.338 0.586
hsa-miR-493 1.986 0.539
hsa-miR-500 2.771 1.297
hsa-miR-642 0.452 1.375
hsa-miR-886-5p 1.221 3.049
Table V. miRNAs expressed only in pathological tissue and not in control 
healthy tissue from the same patients.
hsa-miR-181c hsa-miR-509 5p
hsa-miR-183 hsa-miR-512 3p
hsa-miR-18a hsa-miR-517a
hsa-miR-22 hsa-miR-517c
hsa-miR-331 5p hsa-miR-523
hsa-miR-362 3p hsa-miR-548c 5p
hsa-miR-363 hsa-miR-570
hsa-miR-424 hsa-miR-576 3p
hsa-miR-455 3p hsa-miR-579
hsa-miR-502 3p hsa-miR-583 3p
Table VI. Twenty-three miRNAs expressed only in the N- group, 15 miR-
NAs expressed only in the N+ group. Red: overexpression with respect to 
healthy control tissue from the patients with LSCC; blue: downregulation with 
respect to healthy control tissues from the patients with LSCC; n.e.c.: no ex-
pression change.
N- Fold change N+ Fold change
hsa-miR-146b-
3p
1879 hsa-miR-190 0787
hsa-miR-148b 2455 hsa-miR-486-3p 0047
hsa-miR-338-3p 1043 hsa-miR-542-5p 2795
hsa-miR-339-5p 0359 hsa-miR-618 13980
hsa-miR-485-3p 2172 hsa-miR-198 n.e.c. 
hsa-miR-518b 0829 hsa-miR-342 5p n.e.c. 
hsa-miR-518f 0509 hsa-miR-369 3p n.e.c. 
hsa-miR-627 0827 hsa-miR-373 n.e.c. 
hsa-miR-216b n.e.c. hsa-miR-433 n.e.c. 
hsa-miR-296 n.e.c. hsa-miR-450b 
5p
n.e.c. 
hsa-miR-323 3p n.e.c. hsa-miR-487b n.e.c. 
hsa-miR-372 n.e.c. hsa-miR-545 n.e.c. 
hsa-miR-382 n.e.c. hsa-miR-597 n.e.c. 
hsa-miR-503 n.e.c. hsa-miR-876 3p n.e.c. 
hsa-miR-518c n.e.c. hsa-miR-876 5p n.e.c. 
hsa-miR-529a n.e.c. 
hsa-miR-522 n.e.c. 
hsa-miR-548d n.e.c. 
hsa-miR-582 5p n.e.c. 
hsa-miR-636 n.e.c. 
hsa-miR-651 n.e.c. 
hsa-miR-873 n.e.c. 
hsa-miR-137 n.e.c. 
Expression profile of miRNAs suggestive for nodal metastasis in laryngeal cancer
471
Discussion
Laryngeal tumours identical in site, subsite and clinical 
stage, and subjected to the same treatment may have dif-
ferent clinical outcomes and prognosis, especially when 
considering nodal spreading.
In this study, we analysed the expression of miRNAs in 
tissues resulting from carcinomas of the larynx to identify 
a tissue-specific miRNA signature predictive of unfavour-
able development toward lymph node metastases.
Even if the population under study is very limited in 
number, the results are of considerable interest. The com-
parative data show that the miRNA expression profiles in 
pathological tissues compared to healthy tissues exhibit a 
clear majority of overexpressed miRNAs with only a few 
hypoexpressed miRNAs. 
Some of the miRNAs overexpressed in the diseased tis-
sues have already been described in the literature, also in 
relation to cancer of the larynx:
• miR19a: Marioni et al., recently, have demonstrated 
its higher expression in malignant glottis lesions than 
in benign conditions 16. It was previously correlated 
with neck nodal metastasis, poor differentiation and 
advanced stage when overexpressed 17. 
• miR 27a: it has been shown that miR27a promotes 
proliferation and suppresses apoptosis 18 19.
• miR 155: the expression of tissue and plasma miR155 
is significantly upregulated in patients with LSCC 20; 
furthermore, it seems to play a role in development 
of LSCC in terms of promotion of proliferation and 
invasion 21.
• miR 21: some authors have described its overexpression 
in laryngeal cancer tissues 22 23, and its ratio with miR375 
(miR21/miR375) has been related with worse prognosis 
if high 24 25; and its high expression in serum is associated 
with nodal metastasis in LSCC  26. Recently, miR21 was 
shown to be deregulated by acidic bile and implicated in 
precancerous lesiosn of laryngeal mucosa 27.
• miR 106b: it was found to be upregulated in LSCC 
tissues, together with miR21, and their level were 
found to be increased in poorly/moderately differ-
entiated (G2-G3) cancer tissues and associated with 
lymph node metastasis 28.
• miR 375: according to Wu et al., increased expression 
of miR375 is associated with a more aggressive phe-
notype of LSCC; moreover, a high-level expression of 
miR375 and miR148a in patients with laryngeal dys-
plasia may predict malignant transformation  29. In our 
study, it was downregulated in tumour tissues in agree-
ment with Hu 25. 
• miR 708: it is upregulated in tumour tissues as is 
miR21 and miR205 30 according to our data. 
• miR 205: it is upregulated in tumour tissues (as in our 
study), and in addition it significantly induces cell pro-
liferation and invasion by suppressing CDK2AP1 31.
• miR 221: Yilmaz demonstrated that it is upregulated 
in LSCC plasma samples, but was at normal levels in 
postoperative plasma; he proposed it as a diagnostic 
marker of LSCC 32.
Among the overexpressed miRNAs (fold change between 
2 and 5) in tumour tissues, some have described to be 
down-regulated in patients with LSCC.
• miR 203: according to Tian et al., its lower expression 
is related to poor differentiation, advanced clinical 
stage, lymph node involvement and decreased 5-year 
overall survival 33. Recently, it has been shown to cor-
relate with local disease recurrence after radiotherapy 
in a series of patients with laryngeal cancer 34.
• miR 152: it was described as significantly downregu-
lated in supraglottic laryngeal carcinoma tissues and 
its expression was correlated with p T and p N stages 
in patients with supraglottic LSCC 35. 
• miR 24: its upregulation, similar to miR27a, leads to 
promotion of proliferation and early apoptosis inhibi-
tion in LSCC 18; according to Xu et al., miR24 expres-
sion is significantly lower in LSCC cell lines and it 
inhibits growth-related apoptosis and enhances radio-
sensitivity in LSCC 36.
Of considerable interest are miRNAs detected in our study 
and not yet associated with cancer of the larynx, even 
though they have been previously associated with other tu-
mours. This is the case of six miRNAs: mir9 37, mir511 38, 
mir494  39, mir25  40, mir20  41, and mir10b  42, which are 
greatly overexpressed in several tumour tissues compared 
to healthy control tissues from the same patients. 
Interestingly, we identified some miRNAs with specific 
expression in either N+ or N- cases.
The analysis of the N+ group detected the following 
miRNAs:
• miR618: strongly overexpressed in our study in N+ pa-
tients; it is considered by Hui to be a prognostic factor 
for HNSCC (head and neck squamous cell carcinoma) 43. 
It has been also correlated with thyroid cancer 44.
• miR 542-5p: overexpressed in tumour tissues in our 
series of N+ patients, it was previously reported in 
rhabdomyosarcoma 45 and osteosarcoma 46.
• miR 486-3p: downregulated in tumour tissues of pa-
tients with nodal metastases compared to healthy con-
trol tissues from the same patients, its decreased level 
has been associated with metastasis in cervical cancer 
patients 47.
• miR 135 a: on the basis of our data, this miRNA is 
overexpressed in tumour tissues of N+ patients com-
pared to healthy control tissues and downregulated 
in tumour tissues of patients without lymph node in-
volvement compared to healthy tissue from the same 
patients. Its high expression in gastric cancer tissues is 
more likely to have aggressive characteristics, among 
which lymphatic metastasis 48. 
• miR 20b: overexpressed in tumour tissues of N+ 
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patients, it was associated with laryngeal cancer in 
2010  49; its upregulation promotes proliferation, mi-
gration and invasiveness in oesophageal tumours 50.
• miR 324-3p: overexpressed in tumour tissues of N+ pa-
tients, it is upregulated in plasma of stage I of lung squa-
mous cell carcinoma compared to healthy controls  51; 
furthermore, its low expression might be an important 
marker for prediction of low response to RT/CRT and 
poor overall survival and recurrence-free survival 52.
Analyzing the 12 N- patients, the most interesting miR-
NAs for their biological functions are the following: 
• miR 148b: overexpressed in the diseased tissue of pN- 
patients, it has been linked with melanoma 53.
• miR 339-5p: downregulated in tumour tissues of pN- 
patients, it has been described as a regulator of breast 
cancer progression 54.
• miR 485-3p: overexpressed in the diseased tissue of 
patients without lymph node metastasis, it is described 
as a suppressor of breast cancer metastasis 55.
• miR 518f: downregulated in tumour tissues of pN- pa-
tients compared to control tissue, it is related to endo-
metrial cancer in which it is downregulated 56.
Through analysis of these results, we may define a tissue-
specific miRNA signature that is predictive of lymph node 
metastases in laryngeal carcinoma characterised by 11 
miRNAs, seven of which are overexpressed (upregulated) 
and four downregulated, in particular: miR618, miR542-
5p, let 7b, miR135a, miR20b, miR324-3p, and miR886-
5p are overexpressed; and miR486-3p, miR328, miR376a 
and miR493 are downreguated. This signature is sugges-
tive to be predictive of lymph node involvement even if 
the validation of these results on a wider series of patients 
is strongly warranted.
Conclusions
We have identified a group of miRNAs with characteris-
tic expression profiles in diseased tissues compared to 
matched healthy tissue from the same patients; in addition, 
we have highlighted a miRNA pattern specific of N+ laryn-
geal cancer cases compared to N- cases and healthy tissues. 
Furthermore, the authors have detected a miRNA pattern 
expressed specifically in laryngeal cancer tissues (and not 
in healthy tissues), one expressed exclusively in laryngeal 
cancer with N+ and another one present in N-. These re-
sults are largely innovative, at least in our opinion, and al-
low the identification of a group of potentially specific tu-
mour biomarkers for laryngeal carcinoma that can be used 
to improve its diagnosis, particularly at early stages, and 
to detect patients with minimal residual disease or recur-
rence if the miRNA pattern specific of laryngeal cancer is 
present; but, overall, they can be useful to predict prognosis 
atient in early stages on the basis of the identification of 
the miRNAs signature suggestive for nodal involvement. 
In this case, the miRNAs could lead to tailored treatment.
The technologies of molecular biology are not yet avail-
able in all centres, so that the use of miRNA profiling 
with microarray techniques on large scale in diagnosis 
of laryngeal carcinoma is not readily possible. However, 
the methods of real-time PCR are presently relatively 
cheap and easy to perform. The bottleneck in this type 
of study is, in fact, the identification of differentially 
expressed miRNAs through the use of low-density ar-
rays (as in our case) and their subsequent validation in a 
large population of patients. Once validated, the miRNA 
biomarkers are easy to detect in the tissue of patients 
with cancer and other neoplasms. Another advantage of 
miRNAs is their presence in all body fluids, and in par-
ticular in plasma and serum of patients, in which they 
can be easily detected and quantified 57. A further phase 
of the present study is, in fact, the determination of an 
array of circulating miRNA in serum from the same pa-
tients, which will be determined and cross-referenced 
with those obtained in tissues of the same patients. In 
this way, we can outline a limited group of very reliable 
miRNAs that can be validated (or not) together with a 
“portfolio of prognostic factors” (clinical and pathologi-
cal) for routine use in clinical evaluation. 
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